[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-346414-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-346414-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","large-scale-dna-organization-analysis-of-primary-breast-cancers-for-prediction-of-axillary-lymph-node-metastases","Large-scale DNA organization analysis of primary breast cancers for prediction of axillary lymph node metastases","","Breast cancer causes major mortality worldwide, yet over 60% of patients with primary operable disease have no axillary lymph node metastases, making sentinel lymph node biopsy (SLNB) a source of avoidable morbidity. This study evaluates whether large-scale DNA organization (LDO) features extracted from breast primary biopsy tissue can predict axillary metastases. Random Forest models performed best, with external validation yielding AUC values of 0.711 (LDO only), 0.741 (clinicopathological only), and 0.775 when combined. Key LDO predictors included nuclear radius and staining intensity.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/large-scale-dna-organization-analysis-of-primary-breast-cancers-for-prediction-of-axillary-lymph-node-metastases/346414/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/large-scale-dna-organization-analysis-of-primary-breast-cancers-for-prediction-of-axillary-lymph-node-metastases/346414.png","ImageObject",300,407,{"name":42,"@type":43},"Patrick","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",16,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is sentinel lymph node biopsy (SLNB) not beneficial for many patients?","Question",{"text":63,"@type":64},"More than 60% of primary operable breast cancer patients do not have axillary lymph node metastases, so SLNB can expose many patients to complications without benefit.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What is large-scale DNA organization (LDO) in this research?",{"text":68,"@type":64},"LDO quantifies nuclear characteristics such as nuclear size, shape, and chromatin texture, which are linked to clinical outcomes across cancers, including breast cancer.",{"name":70,"@type":61,"acceptedAnswer":71},"Which model performed best for predicting axillary lymph node metastases?",{"text":72,"@type":64},"Random Forest models performed best. On an external test set, LDO-only features reached AUC 0.711, clinical features reached AUC 0.741, and the combined best model reached AUC 0.775.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},346414,1790142189,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":116,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","The Breast 86 (2026) 104712  \nContents lists available at ScienceDirect  \nThe Breast  \njournal [homepage:](homepage: www.journals.elsevier.com/the-breast)[ www.journals.elsevier.com/the-breast](homepage: www.journals.elsevier.com/the-breast)  \n| Large-scale DNA organization analysis of primary breast cancers for prediction of axillary lymph node metastases\u003Cbr>Nikolay Alabia , Alan Nicholb,c, Fumiya Inabaa, Anita Carraroa, Soufiane El-Hallanid, Martial Guillauda,*\u003Cbr>a Department of Integrative Oncology, British Columbia Cancer Research Centre, Vancouver, BC, Canada\u003Cbr>b Division of Radiation Oncology and Developmental Radiotherapeutics, University of British Columbia, Vancouver, BC, Canada c Department of Radiation Oncology, BC Cancer, Vancouver, BC, Canada\u003Cbr>d Alberta Precision Laboratory, Department of Laboratory Medicine and Pathology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada |  |  | |\n| --- | --- | --- | --- |\n| A R T I C L E I N F O |  | A B S T R A C T |  |\n| Keywords:\u003Cbr>Breast cancer\u003Cbr>Sentinel lymph node biopsy Axillary lymph node metastasis Machine learning\u003Cbr>Predictive modeling\u003Cbr>External validation\u003Cbr>Nuclear morphology Preoperative risk stratification |  | Breast cancer is the leading cause of cancer-related deaths among women worldwide. It is standard practice for patients to undergo a sentinel lymph node biopsy (SLNB) with breast surgery for staging. However, more than 60% of patients with primary operable breast cancers do not have axillary lymph node metastases. Hence, most patients risk complications from SLNB, but do not benefit. There has been considerable research into noninvasive methods for axillary lymph node staging, but few are externally validated. We hypothesized that anew method using large-scale DNA organization (LDO) analysis on a biopsy of the breast primary could predict axillary metastases. LDO, which measures various nuclear characteristics such as the size, shape, and chromatin texture, has been correlated with a variety of clinical outcomes in different cancers, including survival in breast cancer. In this study, we determined that Random Forest models performed best for LDO analysis. On an external test set, our models using LDO features alone achieved an area under the curve (AUC) = 0.711 and clinicopathological features alone achieved AUC = 0.741. Our best and final model using LDO and clinicopathological features together achieved AUC = 0.775. We identified several LDO features that were important for predicting axillary lymph node metastases, including nuclear radius and staining intensity. We present the first histologically-based, externally-validated, and explainable machine learning model capable of predicting axillary lymph node metastases preoperatively. |  |\n\n1. Introduction  \nBreast cancer is the most frequent cancer diagnosed in women worldwide [1]. For these women, accurate axillary lymph node (ALN) staging is crucial for estimating prognosis and choosing the best treatment [2]. The sentinel lymph nodes (SLN) are the ALNs with direct lymphatic drainage from the primary breast cancer [3]. Traditionally, for patients without palpable axillary lymph nodes or abnormal lymph nodes on axillary imaging, sentinel lymph node biopsy (SLNB) is routinely employed to determine whether there are ALN metastases [4]. Although most patients with clinically negative lymph nodes undergo SLNB, more than 60% of primary breast cancers do not have ALN involvement [5]. Accumulating evidence from large randomized trials, including SOUND and INSEMA, demonstrates that SLNB can be safely omitted in select low-risk patients without compromising oncologic  \noutcomes [6,7]. In the INSEMA trial, omission of SLNB in women with clinically node-negative, hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)-negative, grade 1–2 tumors ≤5 cm undergoing breast-conserving surgery was non-inferior to use of SLNB for invasive disease-free survival, with ","cbCaik86hDLOejdR","https://ap.wps.com/l/cbCaik86hDLOejdR","pdf",3080896,"English","# Introduction\n# Study Rationale and Hypothesis\n# Methods Overview: LDO and Model Building\n# External Validation Results\n# Key Predictive LDO Features\n# Clinical Implications","[{\"question\":\"Why is sentinel lymph node biopsy (SLNB) not beneficial for many patients?\",\"answer\":\"More than 60% of primary operable breast cancer patients do not have axillary lymph node metastases, so SLNB can expose many patients to complications without benefit.\"},{\"question\":\"What is large-scale DNA organization (LDO) in this research?\",\"answer\":\"LDO quantifies nuclear characteristics such as nuclear size, shape, and chromatin texture, which are linked to clinical outcomes across cancers, including breast cancer.\"},{\"question\":\"Which model performed best for predicting axillary lymph node metastases?\",\"answer\":\"Random Forest models performed best. On an external test set, LDO-only features reached AUC 0.711, clinical features reached AUC 0.741, and the combined best model reached AUC 0.775.\"}]","Large-scale DNA organization analysis of primary breast cancers for prediction of axillary lymph node metastases | PDF",1790061347,23,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/16e2b3123ad991ff33d905283fc853c1.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b8ee3c92f592e0e0bd9092bb98ea71fd.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ff376275e5df011a07bc525b2c32af1d.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/642df3a882e9ee4e80887b7260eb84e1.webp",980,1306]